Sec. 900.21 Application for approval as a certification agency. State agencies may apply for approval as a certification agency if they have standards at least as stringent as those of Sec. 900.12, qualified personnel, adequate resources to carry out the States as Certifiers' responsibilities, and the authority to enter into a legal agreement with FDA to accept these responsibilities.
(1) An applicant seeking FDA approval as a certification agency shall inform the Director, Division of Mammography Quality Standards (DMQS), Center for Devices and Radiology Health, Food and Drug Administration, 10903 New Hampshire Avenue, Silver Spring, MD 20993, marked Attn: States as Certifiers Coordinator, in writing, of its desire to be approved as a certification agency.
(2) Following receipt of the written request, FDA will provide the applicant with additional information to aid in the submission of an application for approval as a certification agency.
(3) The applicant shall furnish to FDA, at the address in paragraph (b)(1) of this section, three copies of an application containing the following information, materials, and supporting documentation:
(i) Name, address, and phone number of the applicant;
(ii) Detailed description of the mammography quality standards the applicant will require facilities to meet and, for those standards different from FDA's quality standards, information substantiating that they are at least as stringent as FDA standards under Sec. 900.12;
(iii) Detailed description of the applicant's review and decisionmaking process for facility certification, including:
(A) Policies and procedures for notifying facilities of certificate denials and expirations;
(B) Procedures for monitoring and enforcement of the correction of deficiencies by facilities;
(C) Policies and procedures for suspending or revoking a facility's certification;
(D) Policies and procedures that will ensure processing certificates within a timeframe approved by FDA;
(E) A description of the appeals process for facilities contesting adverse certification status decisions;
(F) Education, experience, and training requirements of the applicant's professional and supervisory staff;
(G) Description of the applicant's electronic data management and analysis system;
(H) Fee schedules;
(I) Statement of policies and procedures established to avoid conflict of interest;
(J) Description of the applicant's mechanism for handling facility inquiries and complaints;
(K) Description of a plan to ensure that certified mammography facilities will be inspected according to MQSA (42 U.S.C. 263b) and procedures and policies for notifying facilities of inspection deficiencies;
(L) Policies and procedures for monitoring and enforcing the correction of facility deficiencies discovered during inspections or by other means;
(M) Policies and procedures for additional mammography review and for requesting such reviews from accreditation bodies;
(N) Policies and procedures for patient notification;
(O) If a State has regulations that are more stringent than those of Sec. 900.12, an explanation of how adverse actions taken against a facility under the more stringent regulations will be distinguished from those taken under the requirements of Sec. 900.12; and
(P) Any other information that FDA identifies as necessary to make a determination on the approval of the State as a certification agency.
(1) FDA will conduct a review and evaluation to determine whether the applicant substantially meets the applicable requirements of this subpart and whether the certification standards the applicant will require facilities to meet are the quality standards published under subpart B of this part or at least as stringent as those of subpart B.
(2) FDA will notify the applicant of any deficiencies in the application and request that those deficiencies be corrected within a specified time period. If the deficiencies are not corrected to FDA's satisfaction within the specified time period, FDA may deny the application for approval as a certification agency.
(3) FDA shall notify the applicant whether the application has been approved or denied. The notification shall list any conditions associated with approval or state the bases for any denial.
(4) The review of any application may include a meeting between FDA and representatives of the applicant at a time and location mutually acceptable to FDA and the applicant.
(5) FDA will advise the applicant of the circumstances under which a denied application may be resubmitted.
FDA may limit the scope of certification authority delegated to the State in accordance with MQSA.